Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| With the CrossLink partnership expanded label, combined with increasing morale, improved sales measures and targeting, we believe this is going to be a great year for both products |
| At an institutional level, while supporting enhanced recovery after surgery, both ZYNRELEF and APONVIE can have a positive financial impact on our institutions |
| Implementation of ZYNRELEF and APONVIE as the foundation of our enhanced recovery after surgery protocols, we believe may improve overall patient satisfaction, clinical outcomes and overall quality of life |
| Along with the efficacy, aprepitant also has an excellent safety profile without sharing typical side effects of our commonly used antiemetic therapies such as QT prolongation, sedation, anticholinergic effects or extrapyramidal side effects |
| I would like to reiterate that we anticipate getting to positive EBITDA in Q4 2024 and based on this our strong balance sheet and our current operational plan we do not anticipate having to raise any additional capital |
| We believe ZYNRELEF and APONVIE are both well positioned as we move into 2024 |
| However, through better inventory management and with some renegotiations with our manufacturers, we've been able to reduce COGS and improve gross margins to over 70% |
| We anticipate future gross margins to continue to improve up to the mid-70s range |
| The CrossLink folks have been fantastic |
| We believe we can continue to reduce costs moving forward in this area as we continue to increase efficiencies |
| But look, we're having positive things happen so far and we're pleased so far this has gone as planned |
| As you can see from this slide, we have had a number of significant achievements in 2023 that help us well positioned as we move into 2024 and beyond |
| Both of these projects will provide significant improvement to our product, ZYNRELEF, which is indicated for post-operative surgical pain |
| Our oncology franchise continues to outperform, and I'm happy to report total net revenues of $107.9 million, which exceeded full year 2023 guidance |
| We're also very pleased with ZYNRELEF performance in Q4 of 2023 |
| I really believe the inflection for ZYNRELEF will take place as we move into 2025 after the launch of VAN and having all the new reps fully trained, but we certainly have positive momentum that we believe the CrossLink reps will have an impact in 2024 |
| The oncology franchise continues to outperform our expectations with CINVANTI net revenues coming in at $94.9 million for the year and SUSTOL coming in at $13 million |
| We have been very pleased with the oncology franchise, and we believe these products will continue to show the same consistency as in past years |
| We were very pleased ZYNRELEF hit a record of $5.6 million in net revenue for the quarter, which is the first time this product has ever been over $5 million for the quarter |
| As part of this process, we have also looked to improve our gross margin |
| Our perioperative 1-2 punch for APONVIE and ZYNRELEF will be extremely beneficial to our potential partners at the ASC level |
| For the first time in our history, we were able to do over $5 million in net revenue for the quarter, even while significant change was happening in the business |
| We've been able to reduce operational expenses from $182 million in 2022 to $135 million in 2023 and we should be in the range of $108 million to $160 million in operating expenses in 2024 |
| But we're certainly seeing some positive momentum |
| We are certainly excited to have you join our team |
| Moving now on to our guidance of 2024, we are reaffirming our previously given guidance for revenue of $138 million to $158 million for 2024 and improved gross margins between 68% to 70% |
| Today, we are pleased to update you on our latest achievements in 2023 financial performance, progression on our development projects, CrossLink training and some insight into where we are headed strategically with our products |
| Enhanced recovery after surgery protocols are evidence-based protocols that are essential to patient outcomes and sustaining the financial viability of our health systems |
| We've implemented a comprehensive streamlining of our financial processes, enhancing efficiency and accountability across the organization |
| So with our kind of perioperative one-two punch, we really do feel that these two products are really positioned perfectly with exactly what the ASC is trying to do |
| Statement |
|---|
| The annual margins were negatively impacted by write-offs of ZYNRELEF inventory during the year |
| Postoperative pain and postoperative nausea and vomiting are two of the most common concerns to both patients and clinicians |
| I want to touch on APONVIE, aprepitant injectable emulsion and the current unmet need and lack of awareness |
| Some formularies have been hesitant to adoption due to the limited number of indications, necessitating need for having multiple agent on formulary and subsequent budget impacts |
| The challenges to this program involve a new container closure system and the sterilization process itself |
| But I do want to temper the enthusiasm as obviously this will take time before we really start to hit on all cylinders |
| Postoperative nausea and vomiting is ranked the number one most undesirable post-op complications by patients, but also presents clinical risk factors as well that need to increase length of stay, readmissions and surgical complications |
| The opioid epidemic continues to be at the top of our newsfeeds costing the U.S |
| The net loss was $10.7 million for Q4 2023 and $19.9 million for the comparable period in 2022 |
| And we've given ourselves a little bit of wiggle room, but I don't think you're going to see significant cost reductions from here |
| APONVIE’s safety and efficacy profile for long-acting solution with a 48-hour duration is one of our most significant postoperative complications, postoperative nausea and vomiting |
| And again, it was just very receptive |
| Still comfortable with that number or do you think that's likely to prove conservative? Thanks |
| Please keep in mind that we started implementing our company-wide reduction mid-year 2023 and as mentioned in our previous earnings call, we believe our operational run rate excluding stock compensation and depreciation and amortization going forward will be between $108 million to $160 million and cash burn will decrease every quarter as we have stabilized our spend and revenues are increasing every quarter |
| In addition, overall personnel and related costs decreased due to the reductions in force implemented in June 2022 and June 2023 |
Please consider a small donation if you think this website provides you with relevant information